Samuel Smith highlights that despite common fears around high dividend yields indicating risky businesses, the current market pessimism has unfairly undervalued certain Business Development Companies (BDCs). He explains that some BDCs now offer attractive yields without the expected financial distress, presenting a rare opportunity for investors. Smith shares his criteria for selecting these stocks and recommends specific picks, emphasizing a balance between safety, growth, yield, and value. His insights aim to help investors capitalize on these overlooked high-yield investments.
For readers following high-yield investment opportunities, here is Pluang's market snapshot as of Oct 23, 2026 22:22 WIB: Among 142 priced Financials-sector US stocks tradable on Pluang, 26 rose and 113 fell today. Notable movers include COLB (Columbia Banking System Inc.) at USD 30.98 with a 1-day change of +3.66% and a typical hold time of 8 days, FIGR (Figure Technology Solutions Inc.) at USD 23.16 with a 1-day change of -3.64%, a typical hold time of 4 days, and 100% buy order activity on Pluang, and CBOE (Cboe Global Markets Inc.) at USD 338.65 with a 1-day change of +3.34%, a typical hold time of 4 days, and 100% buy order activity on Pluang.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
